AstraZeneca Opts In To ROR Gamma T Inhibitor Space With Orca Collaboration
This article was originally published in The Pink Sheet Daily
BioMotiv spinout could realize up to $122.5 million under arrangement giving AstraZeneca global option rights to a late-stage preclinical program for producing drugs that regulate production of IL-17.
You may also be interested in...
Sanofi moves into ROR gamma T R&D for potential autoimmune therapies in collaboration with Lead Pharma, while Intrexon acquires Belgium’s ActoGeniX and its platform technology for creating a novel class of biotherapeutics targeting the oral and GI tracts. Teva heads off dispute with Eagle, bringing in new bendamustine formulation.
The drug-discovery specialist is mulling several potential partners for its ROR gamma t inhibitor program, which has potential in autoimmune indications. Two cash-generating deals with Boehringer Ingelheim have made the clinical-stage company self-sufficient for nearly a decade.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.